UK 16:52 Monday, 26 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Early this year we showed the Shorted AIM shares at the start of 2020. How's the performance as at the end of June? (those in bold remain from 2019)...
Early this year we showed the Shorted AIM shares at the start of 2020. How's the performance after the first month of the year? (those in bold remain from 2019)...
Previously writing on Motif Bio (MTFB), in November with the shares above 0.46p I concluded that with clear and significant risk both in delivery from a cash shell and in what the current divestment process will deliver, continue to avoid. The shares last closed at 0.24p but are currently slumping to around 0.15p on the back of a “Corporate Update”…
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2018 and thus far in 2019 (by net short position %, those in bold not on the list at the start of 2019) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
Currently AIM and Nasdaq listed Motif Bio (MTFB) argues “Voluntary Delisting from the Nasdaq Capital Market”. Hmmm – what about those Nasdaq ‘deficiency notices’?...
I warned you all in a bearcast last week that the real threat to Motif Bio (MTFB) was that lender Hercules would start to want its money back and that the company’s cash crisis would thus soon become critical. And lo it came to pass.
Hello Share Tasters. I now always add a warning to any piece I do on medical pioneers. Rewards can be huge if a new drug comes on the market, but the licensing authorities have understandably to be very cautious. A share which I commended to your further research a month ago has just suffered a huge disappointment. US regulators have currently rejected the company’s new iclaprim drug…
